Ben Wan

Ben Wan

Auto-generated profile, based on publicly available information

Ben Wan

Hangzhou Huibo Science and Technology Co., Ltd., Xinjie Science Park, Hangzhou, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2023 in Journal of Materials Science & Technology
Verified
Journal Article
Open access
HHHao Hu
Hao Hu
XLXiao Liu
Xiao Liu
JCJun Chen
Jun Chen
SCShangbin Cui
Shangbin Cui
HYHualin Yi
Hualin Yi
XZXuenong Zou
Xuenong Zou

1 March 2021 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
BWBen Wan
Ben Wan
RWRenxian Wang
Renxian Wang
JNJingjun Nie
Jingjun Nie
YSYuyang Sun
Yuyang Sun
BZBowen Zhang
Bowen Zhang
Dafu ChenDafu Chen
Dafu Chen
Background. Osteosarcoma (OS) patients have a poor response to immunotherapy due to the sheer complexity of the immune system and the nuances of the tumor-immune microenvironment. Methodology. To gain insights into the immune heterogeneity of OS, we identified robust clusters of patients based on the immune gene expression profiles of OS patients in the TARGET database and assessed their reproducibility in an independent cohort collected from the GEO database. The association of comprehensive molecular characterization with reproducible immune subtypes was accessed with ANOVA. Furthermore, we visualized the distribution of individual patients in a tree structure by the graph structure learning-based dimensionality reduction algorithm. Results. We found that 87 OS samples can be divided into 5 immune subtypes, and each of them was associated with distinct clinical outcomes. The immune subtypes also demonstrated widely different patterns in tumor genetic aberrations, tumor-infiltrating, immune cell composition, and cytokine profiles. The immune landscape of OS uncovered the significant intracluster heterogeneity within each subtype and depicted a continuous immune spectrum across patients. Conclusion. The established five immune subtypes in our study suggested immune heterogeneity in OS patients and may provide optimal individual immunotherapy for patients exhibiting OS.

24 June 2025 in Tissue Engineering Part A
Verified
Journal Article
Closed access
MZMengyuan Zhang
Mengyuan Zhang
BWBen Wan
Ben Wan
MSMouyuan Sun
Mouyuan Sun
JSJiafei Sun
Jiafei Sun
YZYi Zhu
Yi Zhu
PSPing Sun
Ping Sun
The immune system and biomaterials exhibit a well-documented synergistic interplay, essential for bone defect healing. Calcium phosphate (CaP) biomaterials, notably hydroxyapatite, β-tricalcium phosphate, and biphasic calcium phosphate, are widely employed as bone substitutes due to their inherent osteoconductivity. A key challenge for synthetic CaPs is augmenting their osteoinductive potential. Indeed, the limited translation of biomaterials into clinical practice may largely stem from insufficient immunomodulatory understanding. Current evidence reveals the complex host immune response to CaPs, which is mediated by physical and biochemical properties. Harnessing immunomodulatory strategies could bridge inflammatory modulation and osteogenesis, thereby enhancing bone regeneration. This review systematically analyzes recent advances in the molecular mechanisms of immune cell responses to CaPs during bone defect healing, deepening our understanding of immunomodulatory strategies for bone regeneration. Furthermore, key knowledge gaps are highlighted to inspire the development of spatiotemporally responsive CaPs for bone tissue engineering.